German registry collecting data on new systemic psoriasis treatments
Part of Bones, joints & muscles, Skin clinical trials.
This study is a psoriasis registry that records real-world information about people starting a systemic (whole-body) treatment for the first time. It helps doctors understand how these treatments work in everyday care and may improve future treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- A dermatologist has confirmed you have plaque psoriasis or psoriatic arthritis
- You are starting a systemic (whole-body) medication for psoriasis for the first time
- You can give informed consent to join the registry
- You can understand and use German well enough to complete the study steps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is a registry that collects information from adults with plaque psoriasis or psoriatic arthritis who are starting a new biologic or other systemic treatment. It helps researchers understand how these treatments are used in real life and what outcomes they may have.
This registry collects information from adults with psoriasis to better understand how psoriasis affects people and how treatments are used in real life. It may help future research and improve knowledge about treatment patterns and outcomes.
This study follows patients with moderate to severe psoriasis who are starting a new advanced medication for the first time. Researchers will track how well the treatment works early on to understand what helps different patients improve.
This study follows people starting a new advanced psoriasis treatment to see how well it works over 16 weeks. You'll have three office visits with your dermatologist, and researchers will track your skin improvement to help understand which treatments work best for different patients.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
This registry is collecting information about people with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis who are starting or needing biologic or targeted medicines. It may help researchers better understand how these treatments work in real life.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.